Dainippon's Phase III Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa

Like the newly-approved Saphris, lurasidone showed little impact on weight and other metabolic parameters in second Phase III PEARL study. The Japanese firm is going for a safety, not efficacy, entry point into the atypical class.